Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on May 10, 2022, covering events occurring on May 4 and May 5, 2022. The filing addresses significant changes in the Company's executive leadership and Board of Directors composition.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CEO: Gerrit Dispersyn, Dr. Med. Sc., departed as President and Chief Executive Officer effective May 5, 2022. He also ceased serving as a director.
- Board Reduction: The Board of Directors reduced its size from eight to seven members following Dr. Dispersyn's departure.
- Interim Appointment: Geert Cauwenbergh, Dr. Med. Sc., a current director, was appointed as interim Principal Executive and Financial Officer effective May 5, 2022.
Compensation and Management Commentary
Severance for Departing CEO: Pursuant to his employment agreement, Dr. Dispersyn is entitled to a cash payment equal to six months of his base salary, subject to the execution of a customary release. Additionally, the Company will contribute to his group medical and dental plan premiums for six months.
Compensation for Interim Officer: Dr. Cauwenbergh will receive a monthly cash payment of $7,500 in connection with his appointment. The filing confirms no family relationships exist between Dr. Cauwenbergh and other directors or officers, and no undisclosed arrangements influenced his appointment.
Background: Dr. Cauwenbergh previously served as the Company's CEO from 2012 to 2019 and has extensive experience in the biopharmaceutical industry, including roles at RHEI Pharmaceuticals, Barrier Therapeutics, and Johnson & Johnson.
Investor Verification Checklist
- Verify the execution of the customary release required for Dr. Dispersyn's severance payment.
- Monitor the timeline for the appointment of a permanent CEO to replace the interim officer.
- Review the Company's cash position to ensure it can meet the severance obligations and interim compensation without impacting operational liquidity.
- Check for any subsequent filings regarding the search for a permanent CEO or further Board changes.